IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

13.06.25 16:01 Uhr

Werte in diesem Artikel

LOS ANGELES, June 13, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of the federal securities laws.

DJS Law Group

Shareholders who purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 14, 2025.    

CASE DETAILS:  The complaint alleges that the Company made false and misleading statements to the market concerning whether Iovance's new Authorized Treatment Centers ("ATCs") suffered from longer timelines to begin treatment with Amtagvi than expected. The Company's sales team and ATCs failed to effectively select patients for Amtagvi, causing patient drop-off. The Company's failure to match ATCs with manufactured product led to lower revenues and higher costs.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

 Eastchester, NY 10709

Phone: 914-206-9742

Email: David@djslawllp.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/iova-shareholders-have-the-right-to-lead-the-iovance-biotherapeutics-inc-securities-lawsuit---contact-the-djs-law-group-to-discuss-your-rights---elv-302480908.html

SOURCE DJS Law Group LLP

In eigener Sache

Übrigens: Iovance Biotherapeutics und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Iovance Biotherapeutics

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Iovance Biotherapeutics

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Iovance Biotherapeutics

Wer­bung

Analysen zu Iovance Biotherapeutics

DatumRatingAnalyst
28.02.2019Lion Biotechnologies BuyChardan Capital Markets
31.12.2018Lion Biotechnologies BuyB. Riley FBR
06.07.2018Lion Biotechnologies BuyChardan Capital Markets
10.04.2018Lion Biotechnologies BuyB. Riley FBR, Inc.
13.03.2018Lion Biotechnologies NeutralB. Riley FBR, Inc.
DatumRatingAnalyst
28.02.2019Lion Biotechnologies BuyChardan Capital Markets
31.12.2018Lion Biotechnologies BuyB. Riley FBR
06.07.2018Lion Biotechnologies BuyChardan Capital Markets
10.04.2018Lion Biotechnologies BuyB. Riley FBR, Inc.
25.01.2018Lion Biotechnologies BuyH.C. Wainwright & Co.
DatumRatingAnalyst
13.03.2018Lion Biotechnologies NeutralB. Riley FBR, Inc.
23.02.2018Lion Biotechnologies NeutralB. Riley FBR, Inc.
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Iovance Biotherapeutics nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen